Pharma Marketing News Vol. 10, No. 19: 21 December 2011
Welcome to Volume 10, Issue #19 (21 DECEMBER 2011) of Pharma Marketing News.
Proposed Rules for Physician Payment Sunshine Act
Looming Challenges Cloud Implementation. This article reviews the strategic implications of the Sunshine Act and also presents highlights of the draft regulations rule released by the Centers for Medicare and Medicaid Services on December 15, 2011.
Certain Physician-Drug Industry Relationships Have Declined Dramatically
The authors of a physician survey published in the November 8, 2010, issue of Archives of Internal Medicine conclude 'given that 83.8% of physicians have PIRs, it is clear that industry still has substantial financial links with the nation's physicians. These findings support the ongoing need for a national system of disclosure of PIRs [Physician-Drug Industry Relationships].' Such a system is part of the Physician Sunshine Law, which is scheduled to go into effect in 2012 with public disclosure of payments scheduled to begin September, 2013.
Politics Vs. Science in the Plan B Decision
Sebelius focused on the fact that Teva's study did not contain data for all ages for which this product would be available for use. According to Tina Raine-Bennett, MD, MPH, of the Women's Health Research Institute at Kaiser Permanente Northern California, a principal investigator of the University of California-San Francisco study, it is unreasonable and virtually impossible to study the use of emergency contraception in 11- and 12-year-olds, because only a small fraction of them will have had sex by that age.
Checking Under the Hood of Pharma Mobile Apps
Let's look 'under the hoods' of two pharma-sponsored mobile apps and compare disclaimers. We'll compare Janssen's PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.
Pfizer Battles to Protect Lipitor Cash Cow
Lipitor Won't Go Gentle Into that Good Generic Night. Pfizer is taking a number of steps to protect it's Lipitor franchise and it hopes that many patients currently taking Lipitor will remain loyal to the brand.
The Changing Pharma eDetailing Landscape
A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.
The Changing Pharma eDetailing Landscape
A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
